RIMONABANT SR141716 IN FEMALE BABOONS

利莫那班 SR141716 在雌性狒狒中的应用

• 批准号: 7716178
• 负责人: RAUL A BASTARRACHEA
• 金额: $ 0.16万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716178
• 关键词: Address; Animals; Anti-Obesity Agents; Banana; Blood specimen; Butter; Computer Retrieval of Information on Scientific Projects Database; Data; Dose; Drug Kinetics; Dyslipidemias; Eating; Fatty acid glycerol esters; Female; Funding; Future; Grant; Hour; Individual; Institution; Investigation; Lipids; Liver; Measures; Metabolic; Metabolic Pathway; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Overweight; Papio; Patients; Peanuts - dietary; Pharmaceutical Preparations; Protocols documentation; Research; Research Personnel; Resources; SR141716; Sampling; Solutions; Source; System; Treatment Protocols; United States National Institutes of Health; Weight Gain; design; diet and exercise; glucose metabolism; lipid metabolism; nonhuman primate; receptor; rimonabant; uptake

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The present study will be undertaken to provide non-human primate data on the uptake, circulatory dynamics, and clearance (pharmacokinetics) of an orally-administered solution of the drug Rimonabant (SRI 417 16). Rimonabant is a recently developed anti-obesity drug that acts on a group of receptors known as the fll1docannabinoid receptors. This system of receptors is overactive in obese individuals and is related to increased food intake, altered lipid and glucose metabolism, and weight gain. Future studies are required to determine the broader metabolic effects of this agent. The present study will provide data to design the dosing protocols for future non-human primate studies that address the effects of Rimonabant on liver fat content and lipid metabolism. Three different doses of tile drug will be given to animals on three different occasions in the form of a sweet treat (banana and peanut butter). Blood samples (10) will be collected periodically for 48 hours following each administration of the agent. Concentrations of active Rimonabant will be measured in these samples and will provide the pharmacokinetic data necessary to determine the optimal dosing regimen for future studies. Presently, Rimonabant is recommended, in conjunction with diet and exercise, in obese patients and in overweight patients with type 2 diabetes or dyslipidemia. The present study and associated future investigations will provide much needed information of the effects of this agent on multiple metabolic pathways and potentially provide information on broader indications for its use.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究将提供有关利莫那班 (SRI 417 16) 口服溶液的摄取、循环动力学和清除（药代动力学）的非人类灵长类动物数据。利莫那班是一种最近开发的抗肥胖药物，作用于一组称为 fl11 二大麻素受体的受体。这种受体系统在肥胖个体中过度活跃，并且与食物摄入量增加、脂质和葡萄糖代谢改变以及体重增加有关。需要进一步的研究来确定该药物更广泛的代谢影响。本研究将为未来非人类灵长类动物研究设计给药方案提供数据，以解决利莫那班对肝脏脂肪含量和脂质代谢的影响。三种不同剂量的瓦片药物将以甜食（香蕉和花生酱）的形式在三种不同的场合给予动物。每次给药后 48 小时内将定期采集血样 (10)。将测量这些样品中活性利莫那班的浓度，并提供确定未来研究的最佳给药方案所需的药代动力学数据。目前，对于患有 2 型糖尿病或血脂异常的肥胖患者和超重患者，建议将利莫那班与饮食和运动相结合。目前的研究和相关的未来研究将提供该药物对多种代谢途径影响的急需信息，并可能提供有关其更广泛使用适应症的信息。